Cell Reprogramming Market Growth & Trends
The global cell reprogramming market size is expected to reach USD 625.92 million by 2030, registering a CAGR of 8.1% over the forecast period, according to a new report by Grand View Research, Inc. Cell reprogramming is known for its capacity to replace damaged cells or tissues, thereby reversing the negative physiological effects it causes. The industry is driven by the growing interest among researchers in the field for the reason that it makes it possible to see and evaluate molecular biological mechanisms like differentiation, epigenetics, and chromatin in ways that were formerly impossibly complex. Furthermore, cellular reprogramming also has a substantial impact on diagnosing and addressing human diseases. Moreover, reprogramming technology is being created & improved; there have also been substantial ongoing advancements in related technologies like gene editing, creation of progenitor cells, & tissue engineering.
The pharmaceutical industry is projected to use the iPSC approach widely to generate effective cell sources, such as iPSC-derived functional cells, to enable drug screening and toxicity assessment. Thus, the growing use of iPSC across the world would propel the demand for cell reprogramming resulting in industry growth. The increase in clinical trials and the wide usage of stem cell therapies around the world are fueling the industry’s expansion. Various academic institutions, biotech & pharmaceutical companies, and government agencies from different nations are focusing on efficient and quick methods for the detection of COVID-19. Mesenchymal stem cells are a safe and efficient method for treating COVID-19, according to a 2020 research article that was published in the academic journal Aging and Disease (2020).
In addition, the lack of efficient treatment for COVID-19 has sparked the attention of the healthcare industry on cell reprogramming technology. As a result, the usage of cell reprogramming technologies is projected to increase during the COVID-19 pandemic. Despite the fact that mesenchymal cells and iPSCs are used in cell reprogramming, there are still several challenges that prevent the market from expanding. The main causes for concern are people’s lack of knowledge about the available treatments and their dread of the unknown therapy. On the other hand, the industry is positioned for growth as a result of the widening pipeline of stem cell therapies, growing interest in customized treatments, and rising healthcare spending. Moreover, the lenient rules that govern stem cell reprogramming in India may play a significant role in luring more businesses to invest in, develop, and market innovative technologies, fueling the continued expansion.
Request a free sample copy or view report summary: Cell Reprogramming Market Report
Cell Reprogramming Market Report Highlights
The mRNA technology segment accounted for the largest share in 2021 due to the increased requirement for easy-to-use technology that offers quick, secure, and effective results
By application, the research segment dominated the global industry in 2021. This is attributed to a rise in the funding by governments as well as other private groups, which is propelling the growth
The research & academic end-user institutes segment dominated the industry in 2021 due to the growing demand for personalized medicines and the cost-effective use of bio-drugs employing this technology
North America led the global industry in 2021 due to the presence of high R&D investment, availability of technologically advanced healthcare research framework, and the development of cell reprogrammed products in the region
Comments